BioCentury
ARTICLE | Clinical News

Panzem NCD 2-methoxyestradiol: Development discontinued

May 12, 2008 7:00 AM UTC

EntreMed reported in its earnings that in March it discontinued development of Panzem NCD for oncology indications because further development would “require the commitment of a disproportionate amoun...